129 related articles for article (PubMed ID: 38412584)
21. Somatic mutations in oral squamous cell carcinomas in 98 Japanese patients and their clinical implications.
Osawa Y; Aoyama KI; Hosomichi K; Uchibori M; Tajima A; Kimura M; Ota Y
Cancer Treat Res Commun; 2021; 29():100456. PubMed ID: 34563788
[TBL] [Abstract][Full Text] [Related]
22. Can we detect biomarkers of oral squamous cell carcinoma from saliva or mouth swabs?
Gaw G; Gribben M
Evid Based Dent; 2022 Mar; 23(1):32-33. PubMed ID: 35338327
[TBL] [Abstract][Full Text] [Related]
23. Current advances in noninvasive methods for the diagnosis of oral squamous cell carcinoma: a review.
Wang S; Yang M; Li R; Bai J
Eur J Med Res; 2023 Jan; 28(1):53. PubMed ID: 36707844
[TBL] [Abstract][Full Text] [Related]
24. Hereditary oral squamous cell carcinoma associated with CDKN2A germline mutation: a case report.
Jeong AR; Forbes K; Orosco RK; Cohen EEW
J Otolaryngol Head Neck Surg; 2022 Feb; 51(1):5. PubMed ID: 35123577
[TBL] [Abstract][Full Text] [Related]
25. Droplet digital polymerase chain reaction for detection and quantification of cell-free DNA TP53 target somatic mutations in oral cancer.
Lin LH; Cheng HW; Liu CJ
Cancer Biomark; 2022; 33(1):29-41. PubMed ID: 34366328
[TBL] [Abstract][Full Text] [Related]
26. Targeted sequencing reveals TP53 as a potential diagnostic biomarker in the post-treatment surveillance of head and neck cancer.
van Ginkel JH; de Leng WW; de Bree R; van Es RJ; Willems SM
Oncotarget; 2016 Sep; 7(38):61575-61586. PubMed ID: 27528217
[TBL] [Abstract][Full Text] [Related]
27. Comparison of mutation landscapes of pretreatment versus recurrent squamous cell carcinoma of the oral cavity: The possible mechanism of resistance to standard treatment.
Payungwong T; Angkulkrerkkrai K; Chaiboonchoe A; Lausoontornsiri W; Jirawatnotai S; Chindavijak S
Cancer Rep (Hoboken); 2024 Mar; 7(3):e2004. PubMed ID: 38477073
[TBL] [Abstract][Full Text] [Related]
28. NOTCH1 mutations as prognostic marker in oral squamous cell carcinoma.
Wu-Chou YH; Hsieh CH; Liao CT; Lin YT; Fan WL; Yang CH
Pathol Res Pract; 2021 Jul; 223():153474. PubMed ID: 33993060
[TBL] [Abstract][Full Text] [Related]
29. Tumor-related markers in histologically normal margins correlate with locally recurrent oral squamous cell carcinoma: a retrospective study.
Wang X; Chen S; Chen X; Zhang C; Liang X
J Oral Pathol Med; 2016 Feb; 45(2):83-8. PubMed ID: 26260282
[TBL] [Abstract][Full Text] [Related]
30. The genomic architectures of tumour-adjacent tissues, plasma and saliva reveal evolutionary underpinnings of relapse in head and neck squamous cell carcinoma.
Wu P; Xie C; Yang L; Liu Y; Zeng J; Li X; Fang X; Fan Y; Zhao S; Kuang N; Xuan T; Xia X; Yi X; Huang Y; Yu Z; Tang Y
Br J Cancer; 2021 Sep; 125(6):854-864. PubMed ID: 34230611
[TBL] [Abstract][Full Text] [Related]
31. Tumour mismatch repair protein loss is associated with advanced stage in oral cavity squamous cell carcinoma.
Vasan K; Satgunaseelan L; Anand S; Asher R; Selinger C; Low TH; Palme CE; Clark JR; Gupta R
Pathology; 2019 Dec; 51(7):688-695. PubMed ID: 31630878
[TBL] [Abstract][Full Text] [Related]
32. Validation of methylation markers for diagnosis of oral cavity cancer.
Arantes LM; de Carvalho AC; Melendez ME; Centrone CC; Góis-Filho JF; Toporcov TN; Caly DN; Tajara EH; Goloni-Bertollo EM; Carvalho AL;
Eur J Cancer; 2015 Mar; 51(5):632-41. PubMed ID: 25686481
[TBL] [Abstract][Full Text] [Related]
33. Potential use of salivary mRNA-based biomarkers to predict oral squamous cell carcinoma.
Tang KD; Weeramange CE; Vider J; Hartel G; West NP; McMillan NAJ; Batstone MD; Liu Z; Vasani S; Kenny L; Punyadeera C
Oral Oncol; 2022 Dec; 135():106215. PubMed ID: 36274347
[No Abstract] [Full Text] [Related]
34. Detection of survivin, carcinoembryonic antigen and ErbB2 level in oral squamous cell carcinoma patients.
Li SX; Yang YQ; Jin LJ; Cai ZG; Sun Z
Cancer Biomark; 2016; 17(4):377-382. PubMed ID: 27662323
[TBL] [Abstract][Full Text] [Related]
35. Functionally impactful TP53 mutations are associated with increased risk of extranodal extension in clinically advanced oral squamous cell carcinoma.
Gleber-Netto FO; Neskey D; Costa AFM; Kataria P; Rao X; Wang J; Kowalski LP; Pickering CR; Dias-Neto E; Myers JN
Cancer; 2020 Oct; 126(20):4498-4510. PubMed ID: 32797678
[TBL] [Abstract][Full Text] [Related]
36. Salivary Porphyromonas gingivalis predicts outcome in oral squamous cell carcinomas: a cohort study.
Chen Q; Shao Z; Liu K; Zhou X; Wang L; Jiang E; Luo T; Shang Z
BMC Oral Health; 2021 May; 21(1):228. PubMed ID: 33941164
[TBL] [Abstract][Full Text] [Related]
37. Assessment of MicroRNA-15a and MicroRNA-16-1 Salivary Level in Oral Squamous Cell Carcinoma Patients.
Koopaie M; Manifar S; Lahiji SS
Microrna; 2021; 10(1):74-79. PubMed ID: 33970852
[TBL] [Abstract][Full Text] [Related]
38. Label-free plasma proteomics for the identification of the putative biomarkers of oral squamous cell carcinoma.
Gautam SS; Singh RP; Karsauliya K; Sonker AK; Reddy PJ; Mehrotra D; Gupta S; Singh S; Kumar R; Singh SP
J Proteomics; 2022 May; 259():104541. PubMed ID: 35231661
[TBL] [Abstract][Full Text] [Related]
39. Role of hyaluronan mediated motility receptor gene in oral squamous cell carcinoma and clinical prognosis.
Tang Y; Xiao Y; Liao R
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2021 Dec; 46(12):1315-1324. PubMed ID: 35232899
[TBL] [Abstract][Full Text] [Related]
40. Salivary
Ueda S; Goto M; Hashimoto K; Imazawa M; Takahashi M; Oh-Iwa I; Shimozato K; Nagao T; Nomoto S
Anticancer Res; 2021 Feb; 41(2):765-772. PubMed ID: 33517281
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
